Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8630858 | 0.97 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL4745749 | 0.95 | PLA2G4A (0.51) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL7279329 | 0.95 | PLA2G4A (0.51) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL4749153 | 0.95 | PLA2G4A (0.51) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL4750053 | 0.95 | PLA2G4A (0.51) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL4745997 | 0.95 | PLA2G4A (0.51) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL4089424 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL15650212 | 0.85 | FDPS (0.50) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL2308601 | 0.85 | LMNA (0.45) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL7289924 | 0.84 | ALDH1A1 (0.45) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
| CN-1040541-C | Polypeptide compound and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-11-04 | — | — | CN | disclosed |
| US-H1638-H | CYCLIC HEXAPEPTIDE | FURUTA TAKAHISA (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0462531-B1 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0729974-A1 | Cyclic polypeptide with antibiotic activity and a process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-04 | — | — | EP | disclosed |
| US-5376634-A | Microbiocides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0486011-A2 | Pharmaceutical composition against Pneumocystis carinii | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| CN-1059729-A | Novel polypeptide compound and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1992-03-25 | — | — | CN | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | ALDH1A1 2751/4885LMNA 2939/4885MAPT 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.